Weill Cornell Medicine (WCM) SPORE in Prostate Cancer

总体总结 前列腺癌(Pca)是西半球最常见的癌症之一，临床表现极为复杂 和分子的异质性。2015年，超过221,800名男性被诊断出患有前列腺癌，其中27,540人死于前列腺癌 美国。我们在PCA的威尔康奈尔医学(WCM)孢子将采取一种新的精准药物 患者护理方法，这将使我们的翻译研究目标与整个PCA的男性护理保持一致 频谱。尽早发现侵袭性前列腺癌将避免较不有效的晚期治疗。我们 将研究如何改善局部性前列腺癌患者的风险评估，以实现最佳治疗选择， 包括主动监视(AS)。患有晚期前列腺癌的男性，尽管接受了下一代雄激素治疗 剥夺疗法(ADT)，屈从于耐药性和疾病进展。我们需要优化医疗保健 通过新的生物标志物和治疗策略将致死性前列腺癌转变为一种慢性可控疾病。 我们注意到，来自其他领域的知识可以增强我们的研究。我们将积极利用 发展研究计划，将来自丰富的多机构环境的研究人员带到 专注于PCA翻译研究。一个可持续的孢子项目需要发展 初级教员(职业提升计划)，他们将在未来几年成为该领域的领导者。水平 垂直科学协作将确保我们利用其他领域的专业知识和经验 孢子，早期检测研究网络(EDRN)，以及直立2癌症(SU2C)和前列腺癌 癌症基金会(PCF)计划。最后，我们会确保研究所产生的资源和数据 将向研究界提供。我们的首要目标是从一开始就影响PCA护理 通过管理晚期状态疾病进行诊断，使用精准医学方法提高 目前的临床护理。 总而言之，PCA中的WCM孢子将成为范式转换翻译研究的主要枢纽。我们会 建立治疗前列腺癌的新方法，这将改善患者的生存和生活质量。

OVERALL SUMMARY Prostate cancer (PCA) is one of the most common cancers in the Western hemisphere, with extreme clinical and molecular heterogeneity. In 2015, over 221,800 men were diagnosed with—and 27,540 died from—PCA in the United States. Our Weill Cornell Medicine (WCM) SPORE in PCA will take a novel precision medicine approach to patient care, which will align our translational research goals with the care of men across the PCA spectrum. The earliest possible detection of aggressive PCA will avoid less effective late-stage therapies. We will study how to improve risk assessment in men with localized PCA to enable optimal treatment choices, including active surveillance (AS). Men with advanced PCA, despite treatment with next generation androgen deprivation therapy (ADT), succumb to drug resistance and disease progression. We need to optimize care through novel biomarker and treatment strategies to change lethal PCA to a chronic manageable disease. We are mindful that knowledge from other fields can augment our research. We will actively use the Developmental Research Program to bring investigators from across a rich, multi-institutional landscape to focus on PCA translational research. A sustainable SPORE program requires development of the careers of junior faculty (Career Enhancement Program), who will be the leaders in the field for years to come. Horizontal and vertical scientific collaborations will ensure that we leverage expertise and experience across other SPOREs, the Early Detection Research Network (EDRN), and the Stand Up 2 Cancer (SU2C) and Prostate Cancer Foundation (PCF) programs. Lastly, we will ensure that resources and data generated from our studies will be made available to the research community. Our overarching goal is to impact PCA care from initial diagnosis through management of advanced state disease using precision medicine approaches to improve current clinical care. In summary, the WCM SPORE in PCA will be a major hub for paradigm-shifting translational research. We will establish new approaches to treating PCA, which will result in improved patient survival and quality of life.